Inclusion Criteria

Inclusion criteria

- Patient with histologically confirmed diagnosis of SCC.

- Patient must not be candidate to direct curative surgery.

- Tumor evaluation by photography with a ruler and CT-scan, MRI or PET-scan must be
performed before enrollment.

- Age ≥ 18 years.

- Karnofsky Performance status (KPS) ≥70.

- Normal laboratory values:

- Platelet count ≥100x103/μL

- Leucocyte count ≥ 3x103/μL

- Hemoglobin ≥ 9 g/dL

- ASAT and ALAT ≤ 2.5xUNL

- Serum creatinine ≤1.5xUNL

- Total bilirubin ≤ 1.5xUNL

- Magnesium ≥ Lower Normal Limit (LLN)

- Calcium ≥ Lower Normal Limit (LLN)

- Patient should agree to perform biopsies and blood collections for translational
research.

- Signed informed consent from the patient or legal representative must be obtained.

Exclusion criteria

- Clinically significant cardiovascular disease (including cardiac insufficiency NYHA
grade III and IV, unstable angina, arrythmia, myocardial infarction, symptomatic
congestive heart failure)in the past 12 months before enrollment.

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
evidence of interstitial lung disease on baseline chest CT scan.

- No prior chemotherapy.

- Prior anti-EGFR therapy.

- Radiation within four weeks prior to trial entry.

- Subject pregnant or breastfeeding, or planning to become pregnant within 6 months
after the end of treatment.

- Subject (male or female) not willing to use highly effective methods of contraception
(per institutional standard) during treatment and for 6 months after the end of
treatment.

- The patient has (or has had) previous or concomitant malignancies at other sites
within last 5years, except effectively treated malignancy that is considered by the
investigator highly likely to have been cured.